Acceleration of α-synuclein aggregation by homologous peptides  by Du, Hai-Ning et al.
FEBS Letters 580 (2006) 3657–3664Acceleration of a-synuclein aggregation by homologous peptides
Hai-Ning Dua, Hong-Tao Lia, Feng Zhangb, Xiao-Jing Lina, Jia-Hao Shia, Yan-Hong Shic,
Li-Na Jib, Jun Hub, Dong-Hai Linc, Hong-Yu Hua,*
a Key Laboratory of Proteomics, Institute of Biochemistry and Cell Biology, Shanghai Institutes for Biological Sciences,
Chinese Academy of Sciences, Shanghai 200031, China
b Shanghai Institute of Applied Physics, Shanghai 201800, China
c Shanghai Institute of Materia Medica, Shanghai Institutes for Biological Sciences, Shanghai 201203, China
Received 22 March 2006; revised 18 May 2006; accepted 19 May 2006
Available online 2 June 2006
Edited by Judit Ova´diAbstract a-Synuclein (a-Syn), amyloid b-protein and prion
protein are among the amyloidogenic proteins that are associated
with the neurodegenerative diseases. These three proteins share a
homologous region with a consensus sequence mainly consisting
of glycine, alanine and valine residues (accordingly named as
the GAV motif), which was proposed to be the critical core for
the ﬁbrillization and cytotoxicity. To understand the role of the
GAV motif in protein amyloidogenesis, we studied the eﬀects
of the homologous peptides corresponding to the sequence of
GAV motif region (residues 66–74) on a-Syn aggregation. The
result shows that these peptides can promote ﬁbrillization of
wild-type a-Syn and induce that of the charge-incorporated
mutants but not the GAV-deﬁcient a-Syn mutant. The accelera-
tion of a-Syn aggregation by the homologous peptides is under a
sequence-speciﬁc manner. The interplay between the GAV pep-
tide and the core regions in a-Syn may accelerate the aggrega-
tion process and stabilize the ﬁbrils. This ﬁnding provides clues
for developing peptide mimics that could promote transforming
the toxic oligomers or protoﬁbrils into the inert mature ﬁbrils.
 2006 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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It is generally considered that protein amyloidogenesis or
ﬁbrillogenesis is closely associated with many neurodegenera-
tive diseases [1,2], such as Parkinson’s disease (PD), Alzhei-
mer’s disease (AD), and prion disease. One pathological
hallmark of these disorders is the deposition of abnormal
ﬁbrillar proteins or peptides in senile plaques or inclusion
bodies in patient brains [3]. a-Synuclein (a-Syn) [4], amyloid
b-protein (Ab) [5] and prion protein (PrP) [6] are the three
most well studied proteins that are prone to aggregation or
even ﬁbrillization both in vivo and in vitro.
Sequence alignment indicated that a-Syn, Ab and PrP share a
homologous hydrophobic region [7,8], normally with a consen-
sus sequence of VGGAVVAGV (Fig. 1A). We named it the
GAV motif [9], as it is mainly comprised of Gly, Ala and Val
residues. Several studies have implicated the conserved se-
quence in the ﬁbrillization and cytotoxicity of the neurodegen-*Corresponding author. Fax: +86 21 54921011.
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106–126) was proposed to be crucial for prion conversion
[10], and a synthetic peptide corresponding to the sequence is
highly amyloidogenic and cytotoxic [11]. Some studies concen-
trated on the central sequence of Ab peptide, suggesting that
Ab14–23 [12] and Ab16–22 [13] are the ﬁbril-generating peptide
fragments, other study indicated that the Ab36–42 fragment
could form very stable ﬁbril with highly ordered structure
and is a key factor determining the aggregation of Ab1–42
[14]. This renders us to reconsider why only Ab40 and Ab42 pep-
tides are neurotoxic and why Ab42 aggregates into ﬁbrils faster
than Ab40 [5]. a-Syn is another amyloidogenic protein of great
interest that is closely associated with the Lewy bodies in Par-
kinson disease [15,16]. Non-amyloid component (NAC), the
central region of a-Syn (residues 61–95), can eﬀectively form
amyloid-like ﬁbrils in vitro [17,18] and the aggregated core is
resistant to proteolysis [19]. The N-terminus of NAC (residues
8–16) has been shown to be the critical core responsible for
aggregation and cytotoxicity [20]. These peptide fragments
readily assemble into ﬁbrils with large content of b-sheet struc-
tures [8]. On the contrary, the C-terminal fragment of NAC
tends to form a-helix structure and likely loses the ability to
aggregate in vitro [8,20]. After studying the conserved sequence
by mutagenesis combined with biochemical characterization,
we previously ascertained that the GAV sequence (66–74) is
essential to a-Syn ﬁbrillization and its cytotoxicity [21].
A growing body of evidence supports the idea that there is a
core region that may play pivotal roles in initiating the aggre-
gation processes of Ab peptides, a-Syn, the N-terminal ﬂexible
segment of PrP and other amyloidogenic proteins [22]. To fur-
ther study the amyloidogenic cores that may have potential
application to drug discovery, we chemically synthesized sev-
eral 9-residue homologous peptides corresponding to the se-
quence of residues 66–74 of a-Syn and biochemically
characterized their abilities to inﬂuence a-Syn aggregation.
Our results show that these short peptides can interact with
a-Syn and accelerate its ﬁbrillization. This will provide further
understanding of the peptide-chain interactions that drive pro-
tein ﬁbrillization and assist in the design of accelerator or
inhibitor for interfering with the amyloidogenic processes.2. Materials and methods
2.1. Peptide synthesis
Three peptides, namely TGV, GAV and GAR (sequences see Fig. 1),
were synthesized by the Boc solid-phase method on a peptide synthe-
sizer and released from the resin by hydrogen ﬂuoride cleavage. Theblished by Elsevier B.V. All rights reserved.
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Fig. 1. Acceleration of a-Syn aggregation by the homologous peptides detected by turbidity. (A) Sequence alignment of the homologous GAV region
from Ab, PrP and a-Syn. The sequence of the TGV peptide corresponds to the residues of 66–74 of a-Syn, while that of the GAV peptide is the
consensus of the GAV region. The GAR peptide is designed for a control, which has two Val residues at positions 5 and 6, respectively, substituted
with Arg. The –NH2 in the C-termini denotes that these peptides are in the amide forms. (B) Incubation of WT a-Syn or D66–74 mutant (2.25 mg/mL)
with diﬀerent concentrations of the GAV peptide (0.3 mg/mL or 0.6 mg/mL). The data were obtained by analyzing the turbidities of the samples at
330 nm after incubation of 24 h. The fresh WT a-Syn was as a control. (C) As in (B), incubation of WT a-Syn (2.25 mg/mL) with the TGV or GAR
peptide (0.3 mg/mL or 0.6 mg/mL). The numerals in the parentheses represent the concentrations of the proteins or peptides (mg/mL). Data shown
are the average of triplicate incubations (means ± S.E.).
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(2.0 · 98 cm). The purity of the peptides was estimated to be greater
than 99% as evidenced by reverse-phase HPLC on a C8 analytical col-
umn (4.6 · 250 mm, Beckman) and amino acid analysis. The peptides
were further veriﬁed by ESI-MS analysis. The molecular weights of
TGV, GAV and GAR are 756.6, 727.6 and 841.6 Da, respectively,
which are in good agreement with the predicted (757.9 Da for TGV,
727.9 Da for GAV, 841.9 for GAR).
2.2. Circular dichroism measurement
CD spectra of the peptide samples were recorded over the wave-
length range 190–250 nm on a Jasco-715 spectropolarimeter. The
peptide samples were diluted to a concentration of 0.2 mg/mL in a
PBS buﬀer (10 mM phosphate, 10 mM NaCl, pH 7.0, with 0.05% so-
dium azide) and transferred into a 1-mm quartz cell. All spectra were
corrected by subtracting the baseline of the buﬀer alone. The param-
eters for recording CD spectra were used as previously reported [23].
Each spectrum was processed by averaging three scans of the sample
and the data were presented as mean residual molar ellipticities
(deg cm2/dmol).
2.3. Experiments for peptide-induced aggregation
Recombinant human a-Syn and its mutants (G68R, G68E and
D66–74) were prepared as previously described [21,24]. In the pep-
tide-induced aggregation experiments, diﬀerent amount of the fresh
peptide was added into the fresh samples of various a-Syn mutants
at a concentration of 2.25 mg/mL in a PBS buﬀer (100 mM phos-
phate, 100 mM NaCl, pH 7.0, 0.05% sodium azide). The mixtures
were incubated in 1.5 mL sterile tubes with continuous shaking at
37 C. The time course of aggregation was monitored by measuringthe turbidity (OD330) [5] and Thioﬂavin T (ThT, Aldrich) ﬂuores-
cence [25]. Fluorescence measurements were performed on a Hitachi
F-4010 ﬂuorophotometer. At an excitation wavelength of 446 nm, the
emission intensities at 482 nm were recorded immediately after addi-
tion of ThT solution [24]. The measurements were carried out in trip-
licate for each sample and the error bars were presented
(means ± S.E.).
2.4. Centrifugal sedimentation analysis
Non-induced and induced a-Syn proteins with a concentration of
2.25 mg/mLwere incubated in PBSbuﬀer at 37 C for 1–2 dayswith con-
tinuous shaking. Samples were ultracentrifuged at 100000 · g for
20 min.Then the supernatant (S) andpellet (P)were loadedon15%poly-
acrylamide gels for electrophoresis followedbyCoomassieBlue staining.
2.5. Atomic force microscopy
The manipulation was as same as the preceding paper [21]. Brieﬂy,
each sample was prepared by displaying 5 lL solution on freshly
cleaved mica. Images were obtained with a commercial AFM facility
(Nanoscope IIIa, Digital Instruments, Santa Barbara, CA) equipped
with a 130 lm · 130 lm scanner (J-scanner) by tapping mode imag-
ing. In order to obtain real height of the ﬁbrils, a minimal force be-
tween the tip and the sample was used. Each sample was observed
in at least ﬁve regions to reduce experimental error. Normally, scan-
ning parameters was varied with individual tip and sample. The
heights of the ﬁlaments were estimated by section analysis with a
software attached in the facility. The morphological data for the ﬁ-
bril species were obtained by averaging a large number of individual
ﬁlaments (n > 25) in at least three individual imaging experiments
(mean ± S.E.).
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Fig. 2. The eﬀects of the GAV peptide on the aggregation of a-Syn and its mutants. (A) Peptide-promoted aggregation of a-Syn protein as monitored
by ThT binding assay. Square, WT a-Syn only; open circle, a-Syn with 0.3 mg/mL GAV peptide; solid circle, a-Syn with 0.6 mg/mL GAV peptide;
open star, a-Syn with 0.3 mg/mL GAR peptide; solid star, a-Syn with 0.6 mg/mL GAR peptide. The free GAV peptide with concentrations of 0.6 mg/
mL (solid triangle) and 1.2 mg/mL (open triangle) were as the controls. (B) Peptide-induced aggregation of a-Syn mutants as monitored by ThT
binding assay. Solid star, D66–74 only; open star, D66–74 with 0.6 mg/mL peptide; solid diamond, G68E only; open diamond, G68E with 0.6 mg/mL
peptide; solid triangle, G68R only; open triangle, G68R with 0.6 mg/mL peptide. The numerals in the parentheses represent the concentrations of the
proteins or peptides (mg/mL). The concentration of a-Syn and the mutants for the above experiments was 2.25 mg/mL. (C) CD spectra of the
aggregates from the G68R mutant. Circle, G68R only for 15-day incubation; triangle, G68R with the GAV peptide for 6-day incubation. (D) CD
spectra of the aggregates from the G68E mutant. Circle, G68E only for 15-day incubation; triangle, G68E with the GAV peptide for 15-day
incubation. The fresh G68R and G68E samples (square) were as the controls.
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The pET3a vector harboringG68Emutant genewas transformed into
E. coli BL21 (DE3). The 15N-labeled protein was expressed in M9 min-
imal medium containing 15NH4Cl and puriﬁed as described in the previ-
ous report [26].AllNMRexperimentswere performedonaVarianUnity
Inova 600 MHz spectrometer at 25 C. 15N-labeled G68E protein
(200 lM) in a buﬀer (100 mM phosphate, pH 6.5) with 8% D2O was
mixed with the GAV peptide (1:2 or 1:10 molar ratio) and incubated at
37 C for several days. The 1H–15NHSQCspectrawere recorded at incu-
bation intervals. The spectra of the peptide-free samples before and after
7-day incubation were also obtained as the controls.3. Results
3.1. Acceleration of a-Syn aggregation by the homologous
peptides
To further understand the role of the GAV motif in a-Syn
ﬁbrillization [21], we studied several homologous peptides
(Fig. 1A). The C-termini of the peptides were capped as
amide to reduce peptide charge and ﬂexibility. As shown in
Fig. 1, both the GAV and TGV peptides can accelerate the
3660 H.-N. Du et al. / FEBS Letters 580 (2006) 3657–3664aggregation of WT a-Syn based on turbidity detection. On the
contrary, the control peptide GAR, in which two central
valines are replaced by the arginine residues, slightly reduces
the aggregation. By means of ThT ﬂuorescence assay, a-Syn
exhibits a faster aggregation rate in the presence of the GAV
peptide with a shorter lag phase of 8–12 h and a slightly in-
creased amount of the aggregates as compared with the
GAV-free sample (Fig. 2A). Intriguingly, the GAV peptide it-
self does not show ﬂuorescence enhancement even at a high
concentration (1.2 mg/mL), suggesting that the increase of
ThT ﬂuorescence intensity at 482 nm originates from the amy-
loid formation of a-Syn rather than from the peptide self-
aggregation. As a comparison, the GAR peptide signiﬁcantly
slows down a-Syn aggregation with a dose-dependent manner.
These results demonstrate that the acceleration of a-Syn aggre-
gation by the homologous peptides is sequence speciﬁc. We
also utilized sedimentation analysis combined with electropho-
resis to examine the role of the two peptides in a-Syn aggrega-
tion. Before incubation, all WT a-Syn molecules are in the
soluble fraction. After incubation of 1–2 days, the majority
of a-Syn molecules are in the pellets in the presence of the
GAV or TGV peptide (Fig. 3A and B), whereas a considerable
amount of a-Syn is retained in soluble fractions in the absence
of the peptides.
3.2. Peptide-induced aggregation of the charge-incorporated
mutants of a-Syn
Our previous study [21] showed that introduction of charged
residues into the GAV motif region (G68R, G68E, etc.) could
reduce ﬁbril formation of a-Syn; and the G68E mutant is much
less potent to form oligomers or short ﬁbrils than G68R. To
realize whether the GAV peptide promotes ﬁbrillization of
these mutants, we examined the aggregation behavior of the
G68R and G68E in the presence of the GAV peptide. As ex-
pected, aggregation of G68R is dramatically accelerated by
the peptide as evidenced by the signiﬁcant shortening of the
lag phase of the aggregation proﬁle (Fig. 2B). Another mutant,Fig. 3. SDS–PAGE for the peptide-induced aggregation of a-Syn and its mu
the GAV peptide: 0.3 mg/mL (the third panel from left), 0.6 mg/mL peptide
sample was as a control. S and P denote the supernatant and pellet, respective
TGV peptide: 0.3 mg/mL (the third panel from left), 0.6 mg/mL peptide (the
(D) D66–74 were incubated for 2 or 6 days with or without the GAV peptide
protein, and the minor bands with smaller molecular weights are probably aG68E, shows only moderately increased aggregation in the
presence of the GAV peptide. CD studies reveal that, with
the assistance of the GAV peptide, G68R undergoes structural
transformation from random coil to b-sheet (Fig. 2C). In con-
trast, incubation of G68E with the GAV peptide causes no sig-
niﬁcant change in far-UV CD spectra except a slight increase
of the ellipticity at around 220 nm (Fig. 2D). As shown in
Fig. 3C, G68R forms a major part of the aggregate deposits
in the presence of the GAV peptide, whereas the peptide-free
sample forms no aggregates even after incubation of 6 days.
These data indicate that the GAV peptide induces aggregation
of G68R more eﬀectively than that of the G68E mutant.
3.3. Peptide-induced ﬁbrillization of G68R and G68E mutants:
AFM evidence
We further compared the AFM images of the a-Syn ﬁbrils
generated in the absence or presence of the GAV peptide.
The images demonstrate that, after incubation of 6 days, the
peptide induces G68R to form abundant ﬁlaments with height
of 5.8 nm and length of over 200 nm (Fig. 4B). Similarly, the
peptide can also induce G68E to form small short ﬁlaments of
6.2 nm in height and around 50 nm in length, but the majori-
ties are oligomers or anomalous aggregates (Fig. 4D). Never-
theless, no ﬁbrils can be visualized in the incubations in the
absence of the GAV peptide even after extending the incuba-
tion time to 15 days (Fig. 4A and C) as previous reported [21].
3.4. Peptide-induced conformational change of G68E mutant
The above results show that the GAV peptide can induce the
ﬁbrillization of charge-incorporated a-Syn mutants. To further
understand the mechanism of the peptide-induced ﬁbrilliza-
tion, we studied G68E, a less potent aggregation mutant, by
1H–15N HSQC NMR experiments. The chemical shifts of the
amides in fresh G68E exhibit small dispersion in the 1H dimen-
sion (Fig. 5A), suggesting that G68E is a natively unstructured
protein similar to WT a-Syn [26]. Incubation of G68E for 7
days has no signiﬁcant eﬀect on the HSQC spectrumtants. (A) a-Syn with the GAV peptide. WT a-Syn was incubated with
(the fourth panel) or without the peptide (the second panel). The fresh
ly. (B) a-Syn with the TGV peptide. WT a-Syn was incubated with the
fourth panel) or without the peptide (the second panel). (C) G68R and
as indicated in the graphs. The major 19-kDa band in a lane is a-Syn
-Syn fragments caused by degradation during incubation.
H.-N. Du et al. / FEBS Letters 580 (2006) 3657–3664 3661(Fig. 5B), suggesting little structural perturbation occurred
during the incubation. This is consistent with the previous re-
sult that G68E cannot self-aggregate into mature ﬁbrils [21].
When the spectra are acquired immediately after mixing
G68E protein with the GAV peptide, no signiﬁcant chemi-
cal-shift change occurs (Fig. 5C and E), suggesting that the
peptide does not rapidly associate with the a-Syn mutant upon
mixing. However, after the mixture is incubated for 7 days,
large chemical-shift changes occur in the spectra (Fig. 5D
and F). Similar results are also obtained with a shorter incuba-
tion of 3 days (data not shown). The higher concentration of
the peptide seems to cause larger eﬀect on the dispersion of
the resonance peaks as shown by the wider dispersion of the
peaks in both dimensions (Fig. 5F, circle indicated). Interest-
ingly, some peaks disappear in the spectra while some new
peaks appear, possibly due to formation of the soluble aggre-
gates. The NMR experiments strongly support that the GAV
peptide can induce conformational change and soluble aggre-
gation of G68E mutant. Combined with CD and other exper-
iments, we propose that G68E mutant can form considerableFig. 4. AFM images of the ﬁbrils from G68R or G68E mutant with the assist
peptide-assistant ﬁbrillization of G68R. (C) Peptide-free G68E sample. (D
samples were incubated for 15 days and the samples with the GAV peptide w
are the average heights of the ﬁbrils. Scale bar, 200 nm.amounts of b-sheet structure in the soluble oligomers or even
ﬁbrils with the assistance of the GAV peptide.
3.5. The GAV peptide fails to trigger aggregation of the GAV-
deﬁcient mutant of a-Syn
Since the GAV-deletion mutant (D66–74) loses the capacity of
ﬁbrillization, we examined whether the GAV peptide could re-
store the aggregation behavior in this a-Syn mutant. Unfortu-
nately, there is no observable turbidity in the mixture of D66–74
and GAV even after an incubation of over 6 days with contin-
uous shaking at 37 C (Fig. 1B). Both ThT ﬂuorescence assay
(Fig. 2B) and SDS–PAGE analysis (Fig. 3D) support the no-
tion that D66–74 does not aggregate into ﬁlaments no matter
the GAV peptide is present or not. This indicates that the
D66–74 mutant has lost not only the capacity of self-ﬁbrilliza-
tion but also the potential of being restored to form ﬁbrils
by the GAV peptide. Taken together, we conclude that the
GAV motif is crucial for a-Syn aggregation, and the interplay
between the GAV peptide and the core regions in a-Syn may
accelerate the aggregation process and stabilize the ﬁbrils.ance of the GAV peptide. (A) Peptide-free G68R sample. (B) The GAV
) The GAV peptide-assistant ﬁbrillization of G68E. The peptide-free
ere incubated for only 6 days. The numerical values beside the graphs
Fig. 5. 1H–15N HSQC spectra of G68E mutant showing the conformational changes during the GAV peptide-induced aggregation. (A) HSQC
spectrum of fresh G68E. (B) HSQC spectrum of G68E after incubation of 7 days. (C) HSQC spectrum of G68E recorded immediately after addition
of the peptide in a 1:2 molar ratio. (D) HSQC spectra of sample (C) recorded after incubation of 7 days. (E) As in (C), except for the molar ratio of
1:10. (F) As in (E), except for incubation of 7 days. For NMR experiments, 200 lM (3.0 mg/mL) of 15N-labeled G68E was incubated with 0.4 mM
(0.32 mg/mL) or 2.0 mM (1.6 mg/mL) peptide in 100 mM phosphate buﬀer (pH 6.5) at 37 C for 7 days. The peaks with a circle (in D and F) indicate
large chemical-shift changes as compared with those of the peptide-free (A and B) or non-incubation (C and E) samples. All the samples in the
presence of the peptide remained clear after acquisition of the HSQC spectra.
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Aggregation or amyloid formation is generally a result of
conformational alternation (such as exposure of hydrophobic
residues) of a natively folded protein or peptide when it is sub-
jected to abnormal conditions such as a mutation or trunca-
tion [1,9]. Even a native peptide chain, such as a-Syn and
PrP, is occasionally found to transform into amyloid ﬁbrils un-
der normal conditions [15]. The GAV motif, which is mainly
comprised of ﬂexible Gly and relatively hydrophobic residues
(Val, Ala), is critical for ﬁbrillization of a-Syn and possibly
for that of Ab and PrP [7,8,21,27]. This particular motif is ex-
actly located in the ‘‘aggregation-prone’’ regions in several
amyloidogenic proteins as predicted by aggregation propensity
proﬁles [28].
Charged mutation (such as G68E and G68R) impedes ﬁbril
formation of a-Syn, but the mutants are still able to form olig-
omers or protoﬁbrils [21]. The present data show that ﬁbrilli-
zation of G68R is more easily induced by the GAV peptide
than that of G68E mutant. It is probably because that G68R
has more intrinsic ability of oligomerization than G68E in
the peptide-free manner (Fig. 4A and C). Our previous study
showed that one group of a-Syn mutants (V66R and G68R)
can generate small short ﬁlaments with diﬀerent sizes while an-
other group (G68E, V70R/V71R) only forms small oligomers
[21]. We propose that the GAV peptide interacts with the
GAV core regions of a-Syn or its mutants by forming hydro-
phobic patches. This is also evidenced by the NMR experiment
that the GAV peptide can trigger the conformational change
of G68E mutant. When forming ﬁbrils, the GAV peptide
chains are entirely embedded into the existing cross b-sheet
core. Formation of the mingled b-strands may facilitate elon-
gation of the ﬁlaments. Because D66–74 and GAR peptide are
deﬁcient of the critical GAV motif, they may have lost the abil-
ity of b-sheet formation by intermolecular chain–chain interac-
tions between protein and peptide. Therefore, ﬁbrillization of
D66–74 cannot be restored by the GAV peptide or the GAR
peptide fails to prompt a-Syn aggregation.
The homologous GAV peptides can not only accelerate the
ﬁbrillization of WT a-Syn but also more interestingly trigger
the ﬁbrillization of charge-incorporated mutants. While the
manuscript was in preparation, El-Agnaf et al. [29] reported
identiﬁcation of residues 64–100 of a-Syn as the binding region
responsible for its self-aggregation. They designed some a-Syn
inhibitors (ASI) based on residues 69–72 of a-Syn with
additional arginine residues in both termini (such as
RGAVVTGR-NH2), and found that these inhibitory peptides
interact with full-length a-Syn and block its self-assembly. This
agrees with our previous work that the hydrophobic region 66–
74 (namely GAV motif) is critical for its ﬁbrillization and cyto-
toxicity [21], and the present result that the interplay between
the homologous GAV peptide and the core regions of a-Syn
may accelerate the aggregation process and stabilize the ﬁbrils.
This is also supported by the fact that the a-Syn aggregation is
indeed accelerated by the homologous GAV peptides, and this
process is dependent on the peptide sequence. On the other
hand, it seems increasingly likely that the early oligomers or
protoﬁbrils during ﬁbrillization process are actually the major
cytotoxic species responsible for neural cell death, whereas the
mature ﬁbrils, such as Lewy bodies, are the inert metabolic
products that may protect cells against impairment [30]. This
implies that reduction of the oligomeric intermediate by inhib-iting protein oligomerization [31–33] or accelerating ﬁbrilliza-
tion via modiﬁed homologous peptides based on the native
sequences of the amyloidogenic proteins might be a practicable
strategy for therapeutic usage in neurodegenerative diseases.
Consistent with this idea, the cell-permeable inhibitor using
the polyarginine peptide delivery system has been developed
for suppressing the cellular impact of a-Syn aggregation [29].
Therefore, our ﬁnding that the homologous peptides can inter-
act with a-Syn and accelerate its ﬁbrillization could be poten-
tially utilized in the development of peptidomimetic drugs that
convert the toxic oligomers into inert mature ﬁbrils in vivo to
treat the related neurodegenerative diseases.
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